Mehdi Mirsaeidi
Chief/Professor/M.D. | University of Florida
Gainesville, FL, UNITED STATES
Dr. Mehdi Mirsaeidi is an expert in ILD, climate change; lung cancer, and bacteriophages.
Biography
Dr. Mehdi Mirsaeidi is a highly skilled medical professional specializing in sarcoidosis, interstitial lung disease (ILD), and pulmonary infections. He is also director of the ILD and Sarcoidosis Program at UF Health in Jacksonville. With extensive expertise in these areas, Dr. Mirsaeidi excels in diagnosing and treating complex cases while also conducting groundbreaking research. Passionate about advancing patient care and outcomes, he is committed to staying at the forefront of medical advancements and implementing novel approaches in his practice. Driven by a deep sense of compassion, Dr. Mirsaeidi strives to provide the highest level of care to his patients, leveraging his knowledge and experience to improve their quality of life. With a strong dedication to education, he also actively contributes to the training and mentorship of future medical professionals.
His lab is interested in studying novel biomarkers that are involved in the mechanism of sarcoidosis, ILD and lung cancer. His team has discovered role of GHRHR in inflammation and lung cancer with a focus on small cell lung cancer (SCLC).
Areas of Expertise (4)
Bacteriophages
Climate Change and Health
Interstitial Lung Disease
Bacterial Drug Resistant
Articles (4)
Investigating Metabolic Phenotypes for Sarcoidosis Diagnosis and Exploring Immunometabolic Profiles to Unravel Disease Mechanisms
MetabolitesMohammad Mehdi Banoei, et. al
2024-12-31
Sarcoidosis is a granulomatous disease affecting multiple organ systems and poses a diagnostic challenge due to its diverse clinical manifestations and absence of specific diagnostic tests. Currently, blood biomarkers such as ACE, sIL-2R, CD163, CCL18, serum amyloid A, and CRP are employed to aid in the diagnosis and monitoring of sarcoidosis.
Complete Genome Sequencing of the Novel Pseudomonas aeruginosa Phage UF_RH1
ASM JournalsAbdolrazagh Hashemi Shahraki, et. al
2023-05-11
Here, we present the genome sequence of a novel Pseudomonas aeruginosa bacteriophage called UF_RH1. This lytic phage has a genome size of 42,567 bp and is classified as a member of the Siphoviridae family and the Septimatrevirus genus. UF_RH1 shares genetic similarities with Stenotrophomonas phage vB_SmaS-DLP_2. Pseudomonas aeruginosa is an opportunistic pathogen that poses significant challenges for treatment.
Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis
Pulmonary TherapyMehdi Mirsaeidi, et. al
2023-04-19
Introduction: Long-term treatment of pulmonary sarcoidosis with glucocorticoids has been associated with toxicity and other adverse events, highlighting the need for alternative therapies. The goal of this study was to evaluate the efficacy and safety of repository corticotropin injection (RCI, Acthar® Gel) in patients with pulmonary sarcoidosis and to validate endpoints for use in future clinical trials.
Management of nontuberculous mycobacteria in lung transplant cases: an international Delphi study
ERJ Open ResearchHuda Asif, et. al
2023-03-07
Rationale: Nontuberculous mycobacterial (NTM) diseases are difficult-to-treat infections, especially in lung transplant (LTx) candidates. Currently, there is a paucity of recommendations on the management of NTM infections in LTx, focusing on Mycobacterium avium complex (MAC), M. abscessus and M. kansasii.
Social